Adenosine in the tuberomammillary nucleus inhibits the hista

Edited by Martha Vaughan, National Institutes of Health, Rockville, MD, and approved May 4, 2001 (received for review March 9, 2001) This article has a Correction. Please see: Correction - November 20, 2001 ArticleFigures SIInfo serotonin N Coming to the history of pocket watches,they were first created in the 16th century AD in round or sphericaldesigns. It was made as an accessory which can be worn around the neck or canalso be carried easily in the pocket. It took another ce

Contributed by Osamu Hayaishi, October 30, 2008 (received for review October 6, 2008)

Article Figures & SI Info & Metrics PDF

Abstract

Adenosine has been proposed to promote sleep through A1 receptors (A1R's) and/or A2A receptors in the brain. We previously reported that A2A receptors mediate the sleep-promoting Trace of prostaglandin D2, an enExecutegenous sleep-inducing substance, and that activation of these receptors induces sleep and blockade of them by caffeine results in wakefulness. On the other hand, A1R has been suggested to increase sleep by inhibition of the cholinergic Location of the basal forebrain. However, the role and tarObtain sites of A1R in sleep–wake regulation remained controversial. In this study, immunohistochemistry revealed that A1R was expressed in histaminergic neurons of the rat tuberomammillary nucleus (TMN). In vivo microdialysis Displayed that the histamine release in the frontal cortex was decreased by microinjection into the TMN of N6-cyclLaunchtyladenosine (CPA), an A1R agonist, adenosine or coformycin, an inhibitor of adenosine deaminase, which catabolizes adenosine to inosine. Bilateral injection of CPA into the rat TMN significantly increased the amount and the delta power density of non-rapid eye movement (non-REM; NREM) sleep but did not affect REM sleep. CPA-promoted sleep was observed in WT mice but not in KO mice for A1R or histamine H1 receptor, indicating that the NREM sleep promoted by A1R-specific agonist depended on the histaminergic system. Furthermore, the bilateral injection of adenosine or coformycin into the rat TMN increased NREM sleep, which was completely abolished by coadministration of 1,3-dimethyl-8-cyclLaunchthylxanthine, a selective A1R antagonist. These results indicate that enExecutegenous adenosine in the TMN suppresses the histaminergic system via A1R to promote NREM sleep.

Adenosine deaminasehistamineknockout mouserat

In 1954, Feldberg and Sherwood (1) Displayed that intraventricular injection of micromole quantities of adenosine into cats caused a state resembling natural sleep of 30-min duration. Subsequent pharmacological studies from several laboratories demonstrated that adenosine and its receptor agonists promoted, but antagonists such as caffeine, inhibited both non-rapid eye movement (non-REM; NREM) and REM sleep (for review, see refs. 2, 3). However, the exact molecular mechanisms underlying sleep–wake regulation by adenosine still remained unclear. Since 1983, we have reported that prostaglandin (PG) D2 is an enExecutegenous sleep-inducing substance in rodents (4) and monkeys (5). PGD2-induced sleep was indistinguishable from natural physiological sleep as judged by several electrophysiological and behavioral criteria (5). Subsequent studies have Displayn that PGD2 is involved in both circadian (6, 7) and homeostatic regulation of sleep (8). Further studies on the molecular mechanisms of sleep–wake regulation by PGD2 demonstrated that PGD2 is produced by the action of lipocalin-type PGD synthase Executeminantly expressed in the leptomeninges (9), binds with PGD receptors (DPRs) exclusively localized in the arachnoid membrane of the basal forebrain (BF) (10), and promotes sleep through adenosine acting at adenosine A2A receptors (A2AR's) (11), followed by activation of sleep-active neurons in the ventrolateral preoptic (VLPO) Spot (12, 13). The somnogenic Trace of PGD2 is mimicked by an A2AR agonist, but not by an adenosine A1 receptor (A1R) one, and is blocked by an A2AR antagonist (11). These findings indicate that the PGD2–A2AR system is involved in both circadian and homeostatic sleep regulation (14).

Among the four subtypes of adenosine receptors, A1, A2A, A2B, and A3 (15), A1R and/or A2AR subtypes have been reported to mediate the sleep-promoting Trace of adenosine. Although A2AR's involvement in the PGD2–VLPO system is clearly established, adenosine via A1R has been proposed to induce sleep by inhibiting the cholinergic Location of the BF (16). For example, the unilateral infusion of the BF with an A1R-selective antagonist increased waking and decreased sleep (17). Single unit recording of BF neurons in conjunction with in vivo microdialysis of an A1R-selective agonist decreased, and an A1R antagonist, increased the discharge activity of the neurons in the BF (18). Moreover, perfusion of A1R antisense oligonucleotides into the BF reduced NREM sleep and EEG delta power (19). However, infusion of an A1R agonist into the lateral ventricle of mice did not alter the amounts of NREM and REM sleep (20). Caffeine, an antagonist for both A1R and A2AR, increased wakefulness in A1R KO mice and in WT mice, but not in A2AR KO mice (21). Therefore, the role of A1R in sleep–wake regulation has remained uncertain.

In the brain parenchyma, adenosine deaminase (ADA), an enzyme which catabolizes adenosine to inosine, is Executeminantly localized in the tuberomammillary nucleus (TMN) of the posterior hypothalamus (22) and is colocalized with histidine decarboxylase (HDC) (23), the key enzyme for histamine synthesis. Histaminergic neurons project from the TMN to most of the central nervous system and have been Displayn to promote wakefulness through histamine H1 receptors (H1R's) (3, 24). However, the functional significance of adenosine and high expression of ADA in the TMN has not been elucidated so far.

In the present study, we found that A1R was coexpressed with ADA in rat TMN and that activation of A1R or inhibition of ADA in the TMN inhibited histaminergic systems to promote NREM sleep without affecting REM sleep, clearly indicating that adenosine in the TMN promotes NREM sleep via A1R's.

Results

Localization of A1R in Histaminergic Neurons of the Rat TMN.

Immunohistochemical staining with polyclonal and monoclonal (25) anti-A1R antibodies revealed that A1R was preExecuteminantly localized in the TMN in the posterior hypothalamus of rats (Fig. 1A). On the other hand, no positive staining was observed in the TMN with anti-A2AR antibody (Fig. 1B) or without the addition of primary antibodies (data not Displayn). Executeuble immunofluorescence staining with antibodies against A1R and HDC (Fig. 1 C–E), a Impresser for histaminergic neurons, or ADA (Fig. 1 F–H) demonstrated that A1R was colocalized with HDC or ADA in the TMN. These results indicate that A1R was expressed in HDC-positive neurons and in ADA-positive ones in the TMN.

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Immunohistochemistry of A1R, A2AR, and HDC in the rat TMN (A–H) and in vivo microdialysis to meaPositive histamine release in the rat FrCx (I–M). (A) Low- and high- (inset to A) magnification views of rat TMN immunostained with polyclonal A1R antibody. (B) Low- and high- (inset to B) magnification views of rat TMN after incubation with anti-A2AR antibody. (C–E) Executeuble immunofluorescence staining for A1R (C, red) and HDC (D, green) in rat TMN and their merged view (E). (F–H) Executeuble immunofluorescence staining for A1R (F, red) and ADA (G, green) in rat TMN and their merged view (H). (I) Coronal section of a rat injected with coformycin into the TMN and immunostained with anti-HDC antibody to identify the TMN (stained brown and indicated by the arrowhead). The arrow indicates the trace of the injection cannula. 3V, third ventricle. (J) Schematic representation of the implantation sites for the guide cannulae 3 mm above the TMN and injection sites (Left) and microdialysis probe in the FrCx (Right) of rats. Figures of coronal sections are from the stereotaxic atlas of Paxinos and Watson (37). (K–M) Histamine release from the FrCx after administration with CPA (K), adenosine (AExecute, L), or coformycin (CF, M) into the rat TMN. The mean value of histamine outPlace during 1 h before injection was defined as the basal outPlace, and the subsequent Fragments were expressed as percentages of this value. Values are means ± SEM (n = 5–7). *, P < 0.05; **, P < 0.01, significantly different from the vehicle injection, assessed by two-way ANOVA followed by Fisher's probable least-squares Inequity test.

Inhibitory Action of A1R in Histaminergic Systems of the Rat TMN.

To monitor the regulation of histaminergic systems by A1R or ADA, we determined the histamine release from the frontal cortex (FrCx) after a bolus injection of a selective A1R agonist, N6-cyclLaunchtyladenosine (CPA), its natural agonist, adenosine, or an ADA inhibitor, coformycin, into the TMN in urethane-anesthetized rats (Fig. 1J). The CPA administration into the TMN (0.17–1.5 nmol/side) induced a reImpressable Executese-dependent decrease in the histamine release from the FrCx for 2 h after the injection (Fig. 1K). The adenosine administration (2.7 or 4.5 nmol/side) also induced a significant decrease in the histamine release for 1 h after the injection in a Executese-dependent manner (Fig. 1L), although the inhibition of the histamine release was weaker and shorter than in the case of CPA. The injection of coformycin (1.3 or 4 nmol/side) also decreased the histamine release for 1 h from 1 h after the injection (Fig. 1M). These results indicate that the stimulation of A1R's in the TMN with CPA or adenosine and the inhibition of ADA with coformycin suppressed the activity of histaminergic systems in the TMN to decrease the histamine release in the FrCx.

NREM Sleep Promotion by Activation of A1R in the Rat TMN with CPA.

We then examined the sleep–wake profile after a bilateral injection of CPA into the TMN of freely moving rats at 22:00, when such animals spend most of their time in wakefulness. Typical examples of EEG, electromyogram (EMG), and hypnograms from rats given vehicle or CPA at a Executese of 1.5 nmol/side are Displayn in Fig. 2A. The CPA (1.5 nmol/side) injection reImpressably increased NREM sleep for 3 h from 22:30 to 01:30, as compared with the case of the vehicle injection.

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Increase in NREM sleep after CPA injection into the rat TMN. (A) Typical examples of EEG, EMG, and hypnograms after administration of vehicle (Upper panel) or CPA at a Executese of 1.5 (Lower panel) nmol/side. (B) Time courses of NREM and REM sleep in rats treated with CPA at 1.5 nmol/side. (C) NREM and REM sleep over a 4-h period after injection of CPA. (D) Number of NREM sleep bouts for 4 h after injection of CPA (Upper panel) and the numbers of stage transition from NREM (N) to wakefulness (W), wakefulness to NREM, NREM to REM (R), and REM to wakefulness in 4 h after the injection of CPA (Lower panel). *, P < 0.05; **, P < 0.01, significantly different from the vehicle injection. (E) EEG power density curve during NREM sleep for 4 h after injection of CPA. The power of each 0.25-Hz bin was averaged across the sleep stages and normalized as a group by calculating the percentage of each bin from the total power (0–24.75 Hz). The horizontal bars indicate where there is a statistical Inequity (P < 0.05) between vehicle and CPA at 1.5 (red) or 4.5 (purple) nmol/side. Values are means ± SEM (n = 5–7).

As Displayn in Fig. 2B, CPA at 1.5 nmol/side significantly increased the hourly NREM sleep time by 4.6-, 2.1-, 2.5-, and 2.1-fAged during the first, second, third, and fourth hour, respectively, after the injection as compared with the vehicle injection. Enhancement of NREM sleep by the CPA injection concomitantly decreased wakefulness, but did not affect REM sleep. No additional disruption of sleep architecture was observed during the subsequent period. Similar time course profiles were observed with the high (4.5 nmol/side) and middle (0.5 nmol/side) Executeses of CPA. When CPA at a Executese of 0.17 nmol/side was administered, no significant change was found in the sleep–wake profile.

The Executese-dependency of NREM sleep promotion by the CPA administration is summarized in Fig. 2C. When the vehicle solution or CPA at 0.17 nmol/side was administered into the TMN, no Inequity was found in the sleep–wake cycle as compared with the vehicle injection. CPA given at 0.5 and 1.5 nmol/side significantly increased the total amount of NREM sleep during 4 h after the injection by 2.1- and 3.1-fAged in comparison with the vehicle injection, whereas REM sleep was not affected. When CPA at 4.5 nmol/side was administered, NREM sleep during 4 h after the injection was increased by 3.0-fAged without affecting REM sleep, similar to the case of the 1.5 nmol/side, suggesting that these Executeses of CPA almost completely activated A1R's in the TMN.

When we determined the NREM sleep bout distribution for 4 h after the CPA injection (Fig. 2D), the CPA treatments (0.5–4.5 nmol/side) decreased the number of the shorter NREM sleep bouts (60–120 sec) and increased the number of the prolonged ones (>240 sec) in a Executese-dependent manner as compared with the vehicle injection. On the other hand, the CPA administration did not affect the numbers of stage transition from NREM sleep to wakefulness, wakefulness to NREM sleep, NREM to REM sleep, and REM sleep to wakefulness. These results suggest that CPA did not increase the total number of NREM sleep bouts but extended the duration of NREM sleep.

Also, CPA administration into the TMN increased the delta power density of NREM sleep (Fig. 2E). CPA at 1.5 or 4.5 nmol/side significantly increased the peak of the power density curve in the delta range of 0.5–4.0 Hz as compared with the vehicle. The low Executese of CPA (0.17 or 0.5 nmol/side) Displayed a tendency to increase the power density curve of the delta range, although the Inequity was not statistically significant. These results clearly indicate that activation of A1R in the Executese-dependent TMN increased the amount and the delta power density of NREM sleep.

NREM Sleep Promotion by Activation of A1R in the TMN of WT but not KO Mice for A1R or H1R.

To investigate the specificity of CPA against A1R in vivo, we bilaterally injected CPA into the TMN of WT and A1R KO mice of the same littermates (Fig. 3A). CPA at 0.3 nmol/side increased NREM sleep in the WT mice by 1.8-, 3.4-, 1.7-, and 2.4-fAged during the first, second, third, and fourth hour, respectively, after the injection as compared with that of the baseline day. However, A1R KO mice did not display any significant changes in NREM sleep after the CPA administration. The total amount of NREM sleep for 4 h after administration of CPA at 0.3 nmol/side increased by 2.1-fAged in the WT mice from the baseline, whereas no Inequity was observed in the A1R KO mice (Fig. 3B), indicating that A1R is crucial for the increased NREM sleep by CPA injected into the TMN. When CPA (0.3 nmol/side) was administered to the TMN of WT and histamine H1R KO mice, the NREM sleep was significantly increased in WT mice by 2.9-, 4.9-, and 2.4-fAged during the first, second, and fourth hour, respectively, after the injection (Fig. 3C), giving a 2.8-fAged increase during 4 h after the injection (Fig. 3D) from the baseline, but not in the H1R KO mice at all. However, REM sleep was not affected by the treatment of CPA in WT, A1R KO, or H1R KO mice. These results clearly indicate that the increased NREM sleep by activation of A1R's in the TMN depended on the H1R-related arousal system.

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

NREM sleep increase after administration of CPA (0.3 nmol/side) into the TMN of WT, but not A1R or H1R KO, mice. (A and C) Time courses of NREM and REM sleep after CPA treatment of WT and KO mice for A1R (A) or H1R (C). (B and D) NREM and REM sleep during a 4-h period after the injection of CPA into WT and KO mice for A1R (B) or H1R (D). Values are means ± SEM (n = 5–6). *, P < 0.05; **, P < 0.01, significantly different from the baseline.

NREM Sleep Promotion by Administration of Adenosine or ADA Inhibitor, Coformycin, to the Rat TMN.

We then examined the Traces of the bilateral injection of adenosine or coformycin into the TMN on the sleep–wake profile of rats. The time courses of NREM and REM sleep after administration of adenosine and coformycin are Displayn in Fig. 4 A and B, respectively. Adenosine at 4.5 nmol/side significantly increased the hourly NREM sleep time by 2.2-, 2.6-, and 1.8-fAged during the first, second, and third hour, respectively, as compared with the vehicle injection. Coformycin at 4 nmol/side also induced a significant increase in NREM sleep, by 2.0- and 1.8-fAged during the third and fourth hour, respectively, with a lag time of ∼2 h after the injection, similar to the pattern of decrease in the histamine release. Enhancement of NREM sleep by the injection of adenosine or coformycin concomitantly decreased wakefulness, but neither affected the amount of REM sleep nor disrupted additional sleep architecture during the subsequent period. Similar time course profiles were observed with the middle Executese (2.7 nmol/side) of adenosine or the low (1.3 nmol/side) and high (12 nmol/side) Executeses of coformycin. No significant change was found in the sleep–wake profile at a low Executese of adenosine (1.5 nmol/side).

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

NREM and REM sleep after administration of adenosine or coformycin into the rat TMN in the absence or presence of an A1R antagonist. (A–B) Time courses of NREM and REM sleep in rats administered adenosine (AExecute) at 4.5 nmol/side (A) or coformycin (CF) at 4 nmol/side (B). (C) NREM and REM sleep during a 4-h period after the injection of adenosine or coformycin with and without the A1R antagonist CPT. Values are means ± SEM (n = 5–8). *, P < 0.05; **, P < 0.01, significantly different from the vehicle injection.

The Executese-dependency of NREM sleep promotion during 4 h after the administration of adenosine or coformycin is summarized in Fig. 4C. As compared with the vehicle injection, adenosine did not alter the total amount of NREM sleep at a Executese of 1.5 nmol/side but increased the amount of NREM sleep by 1.5- and 1.8-fAged at Executeses of 2.7 and 4.5 nmol/side, respectively, in a Executese-dependent manner. On the other hand, coformycin increased the total amount of NREM sleep weakly at a Executese of 1.3 nmol/side and 1.9- and 1.7-fAged at 4 and 12 nmol/side, respectively, suggesting that the latter two Executeses of coformycin almost completely inhibited ADA in the TMN. However, the treatment with adenosine (1.5–4.5 nmol/side) or coformycin (1.3–12 nmol/side) did not change the amount of REM sleep. These results suggest that NREM sleep was promoted by the increased adenosine level in the TMN after the adenosine administration or the inhibition of ADA with coformycin.

Abolishment of Increased NREM Sleep by Adenosine or ADA Inhibitor with an A1R Antagonist.

The increase in NREM sleep by administration of adenosine (4.5 nmol/side) or coformycin (4 nmol/side) into the rat TMN was completely suppressed by the coadministration of it with 1,3-dimethyl-8-cyclLaunchthylxanthine (CPT; 0.2 nmol/side), a selective A1R antagonist (Fig. 4C). On the other hand, the injection of CPT per se at the same Executese did not produce significant changes in NREM sleep. These results suggest that the NREM sleep, increased by the elevated adenosine level in the TMN, depended on A1R's. Moreover, CPT at 0.4 nmol/side significantly decreased NREM sleep by 26% as compared with the vehicle injection, suggesting that A1R in the TMN is also involved in physiological sleep. Because of the poor solubility of CPT, we could not examine its Trace on the sleep profile at concentrations >0.4 nmol/side. We did not find significant changes in the REM sleep by the CPT treatment. These results, all toObtainher, indicate that the increased adenosine level by adenosine injection or by inhibition of ADA in the TMN promoted the NREM sleep via A1R's.

Discussion

In this study, we demonstrated that administration of exogenous adenosine or inhibition of ADA in the TMN suppressed the histaminergic arousal system and increased the amount of NREM sleep. This Trace was mimicked by activation of A1R with its agonist CPA and abolished with the antagonist CPT. These findings clearly indicate that A1R mediates the inhibition of the TMN by adenosine to promote NREM sleep. Murillo-Rodriguez et al. (26) reported that an A1R agonist increased sleep after perfusion into the BF, and Strecker et al. (17) found that the unilateral infusion of an A1R-selective antagonist into the BF decreased sleep. We also confirmed that microinjected CPA at 1.5 nmol/side into the BF increased sleep to a lower extent than that given into the TMN (data not Displayn). In Dissimilarity, Methippara et al. (27) reported that administration of an A1R agonist into the lateral preoptic Spot induced wakefulness. These findings indicated that the somnogenic or arousal Trace via A1R is a Location-dependent one and are in Excellent agreement with our previous finding that sleep amounts were not changed at all when an A1R agonist was infused into the lateral ventricle of mice (20).

Our study Displayed that adenosine is an enExecutegenous suppressor of the histaminergic arousal system. Sherin et al. (28) previously reported the GABAergic and galaninergic innervations of histaminergic TMN neurons from the sleep-active VLPO neurons. We previously identified GABA release in the TMN to inhibit the histaminergic system (29). Synaptic co-release of ATP and GABA has already been demonstrated (30, 31). Therefore, ATP co-released with GABA from the VLPO neurons may be a source of adenosine acting as a suppressor in the TMN. On the other hand, we previously reported that the extracellular level of adenosine was increased in the subarachnoid space under the rostral BF after stimulation of DPRs on the arachnoid membrane with PGD2 (10). The highest DPR immunoreactivity was found in the arachnoid membrane at the basal aspect of the TMN (10). Thus, the adenosine increased by stimulation of DPR in the arachnoid membrane Arrive the TMN may also suppress the histaminergic system.

ADA is Executeminantly localized in the TMN in the brain parenchyma (22) and has been used as a convenient immunohistochemical Impresser of histaminergic neurons. However, the physiological function of ADA has not yet been elucidated. Our study clearly Displayed that ADA in the TMN is involved in the sleep–wake regulation, because treatment of the TMN with the ADA inhibitor coformycin decreased the histamine release in the FrCx and increased NREM sleep. These findings also suggest that enExecutegenous adenosine suppressed the TMN to Sustain the NREM sleep presPositive under the physiological condition. ADA may decompose local adenosine in the TMN to avoid excessive suppression of the TMN by adenosine.

We found that the A1R-mediated suppression of the histaminergic system increased both the duration (Fig. 2D) and the delta-power density (0.5–4 Hz) of NREM sleep (Fig. 2E). Similar Traces were reported by Retey et al. (32), who found that humans with a genetic variant of ADA, which is associated with the reduced metabolism of adenosine to inosine, Presented enhanced deep sleep and Unhurried-wave activity (power within ≈0.5–5 Hz) during sleep. These observations suggest that the regulation of the histaminergic system by adenosine may be involved in the duration and Unhurried-wave activity of NREM sleep.

We found that the A1R-mediated suppression of the histaminergic system extended NREM sleep duration without affecting the total number of NREM sleep bouts in rats (Fig. 2D), suggesting that the histaminergic systems were involved in the termination of NREM sleep by inducing wakefulness. This interpretation is consistent with our previous finding that H1R KO mice Displayed prolonged duration of NREM sleep episodes as compared with WT mice (33). In Dissimilarity, Takahashi et al. (34) proposed that histaminergic neurons play an Necessary role in the maintenance of the vigilance but not in the induction of wakefulness per se, because they found that these neurons Present a pronounced delay in firing during transitions from sleep to wakefulness, as judged from the extracellular single-unit recordings for the histaminergic tuberomammillary neurons in mice. Thus, further analyses are expected to reveal the contribution of the histaminergic system to the switching from NREM sleep to wakefulness.

Direct activation of A1R's or inhibition of ADA in the TMN increased NREM sleep but not REM sleep, suggesting that the histaminergic system is closely related to the regulation of NREM sleep and wakefulness and consistent with the evidence that H1R KO mice Display a decreased number of transition states between wakefulness and NREM sleep but not REM sleep (33). Alternatively, we previously Displayed that a PGD2 or A2AR agonist suppresses the histaminergic system (12, 13, 29) and increases both NREM and REM sleep (4, 11). For example, an A2AR agonist (2 pmol/min) increased Unhurried-wave sleep (NREM sleep) by 71% and paraExecutexical sleep (REM sleep) by 96% in rats (11), whereas an A1R one at 1.5 nmol/side increased NREM sleep by 3.1-fAged but did not change the amount of REM sleep at all (Fig. 2C). The fact that a PGD2 or A2AR agonist activates sleep-active neurons in the VLPO (12, 13), which innervates histaminergic neurons in the TMN and other monoaminergic arousal nuclei, such as serotonergic neurons in the Executersal raphe nucleus and noradrenergic neurons in the locus ceruleus (28), suggests that inhibition of these arousal neurons may be involved in the increase in both NREM and REM sleep. These findings suggest that the histaminergic system relatively selectively regulates the transition between wakefulness and NREM sleep.

In conclusion, the activation of A1R's expressed in the TMN led to inhibition of the histaminergic system and promotion of NREM sleep.

Materials and Methods

Animals and Chemicals.

Male Sprague–Dawley rats, weighing 280–320 g (8–10 weeks Aged), were purchased from Japan SLC Inc. A1R KO mice (35) and H1R KO mice (36) by T. Watanabe, RIKEN Institute, were Sustained at Oriental Bioservice, Japan. Both male KO mice and their respective WT littermates of inbred C57BL/6 strain, weighing 20–26 g (10–12 weeks Aged), were used in these experiments. They were housed at an ambient temperature of 22 ± 0.5 °C with a relative humidity of 60 ± 2% on an automatically controlled 12:12 h light/ShaExecutewy cycle (light on at 08:00, illumination intensity ≈100 lux). They had ad libitum access to food and water. The experimental protocols were approved by the Animal Care Committee of Osaka Bioscience Institute.

Coformycin (Calbiochem), CPA, CPT, and adenosine (Sigma) were dissolved in artificial cerebrospinal fluid (composition: 140 mM NaCl, 3 mM KCl, 1 mM MgCl2, 1.3 mM CaCl2, 2 mM Na2HPO4, 0.2 mM NaH2PO4, and 4.5 mM glucose; pH 7.4). Aliquots were prepared and frozen at −20 °C and thawed immediately before each experiment.

EEG and EMG Recordings.

Under pentobarbital anesthesia (50 mg/kg, i.p.), rats or mice were chronically implanted with EEG and EMG electrodes for polysomnographic recordings (29, 33) and two guide cannulae (outer diameter, 0.55 mm) for drug application. The two guide cannulae were inserted stereotaxically at positions of anteroposterior (AP) −4.52 mm; left–right (LR) −0.8 mm; Executersoventral (DV) −6.2 mm from bregma; 3 mm above the TMN for rats as Displayn in Fig. 1J or AP −2.46 mm; LR −1.0 mm; DV −3.5 mm from bregma; 2 mm above the TMN for mice according to the atlases (37, 38). The EEG electrodes, both cannulae, and two stainless steel screws for anchorage were fixed to the skull with dental cement. Two stainless steel wires were Spaced into neck muscles as EMG electrodes. After 10 days for recovery, each animal was connected to an EEG/EMG recording cable in a soundproof recording chamber and habituated for 3 days before polygraphic recording. The EEG/EMG signals were amplified, filtered (EEG, 0.5–30 Hz; EMG, 20–200 Hz), digitized at a sampling rate of 128 Hz, and recorded by using SLEEPSIGN software ver. 3 (Kissei Comtec, Japan) (39).

Pharmacological Treatment.

Baseline recordings were taken for 24 h from 20:00. At 22:00 on the next day, CPA, adenosine, coformycin, CPT, or vehicle solution (0.4 μl) was injected bilaterally through the cannula (outer diameter, 0.25 mm) inserted into the TMN. To verify Accurate Spacement of injection sites, we performed immunohistochemical staining for HDC after EEG/EMG recordings, which staining indicated that the injection cannula reached the TMN (Fig. 1I).

Vigilance State Analysis.

The vigilance states were classified off-line in 10-sec epochs into REM sleep, NREM sleep, and wakefulness by SLEEPSIGN automatically, according to the standard criteria (21). As a final step, defined sleep–wake stages were examined visually and Accurateed if necessary.

In Vivo Microdialysis Procedure for MeaPositivement of Histamine Release.

Under urethane anesthesia (1.2 g/kg, i.p.), rats were implanted with a microdialysis probe (outer diameter, 0.22 mm; Eicom) into the FrCx (AP + 3.2 mm; LR −1.0 mm; DV −3.5 mm; membrane length, 2 mm) for monitoring extracellular histamine; and two stainless steel cannulae were introduced into the TMN for administration of CPA, adenosine, or coformycin, as Characterized above. The microdialysis probe was perfused with artificial cerebrospinal fluid at a flow rate of 2 μl/min. Two hours after insertion of the microdialysis probe, dialysates were continuously collected from the FrCx at 20-min intervals (40 μl each) from 1 h before injection of the drug to the TMN through the cannula to 4 h after the injection. The dialysates were kept at −20 °C until the histamine assay could be performed by HPLC fluorometry (33).

Immunostaining for Detection of Adenosine Receptors in the Rat TMN.

Under deep pentobarbital (50 mg/kg, i.p.) anesthesia, rats were perfused via the heart with PBS followed by 10% formalin solution. The brains were removed and immersed in the same fixative overnight at 4 °C, embedded into paraffin, and Slice into 10-μm sections with a microtome. The sections were incubated with rabbit anti-A1R antibody (1:100; Sigma), raised against amino acid 309-326 of the rat A1R; mouse anti-A1R antibody (1:100) (25) provided by T. Ochiishi, National Institute of Advanced Industrial Science and Technology, Japan; mouse anti-A2AR antibody (1:1000; Upstate); or guinea pig anti-HDC antibody (1:5000; Euro-Diagnostica). They were then incubated with biotinylated anti-rabbit IgG antibody (1:400; Vector), anti-mouse IgG antibody (1:400; Vector) or anti-guinea pig IgG antibody (1:400; Vector), followed by horseradish peroxidase-conjugated avidin (Vectastain kit; Vector). These immunoreactivities were visualized by incubation with 3,3′-diaminobenzidine.

For Executeuble labeling for A1R and HDC, the sections were incubated with rabbit anti-A1R antibody (1:100) and guinea pig anti-HDC antibody (1:5000) followed by biotinylated anti-rabbit IgG antibody, Alexa-594-conjugated streptavidin (1:400; Invitrogen), and fluorescein-conjugated anti-guinea pig IgG antibody (1:400; Jackson ImmunoResearch). For Executeuble labeling for A1R and ADA, the sections were incubated with rabbit anti-A1R antibody (1:100) and sheep anti-ADA antiserum (1:1000) (40) provided by Rodney E. Kellems, University of Texas-Houston Medical School, followed by biotinylated anti-rabbit IgG antibody, Alexa-594-conjugated streptavidin, and fluorescein-conjugated anti-sheep IgG antibody (1:400; Jackson ImmunoResearch). These signals were observed under a DM IRE2 fluorescence microscope (Leica).

Statistical Analysis.

All data were expressed as the mean ± SEM (n = 5–8). The statistical significance of time course data for sleep–wake profiles and histamine release, total sleep amounts, and the Trace of CPA on the number of NREM sleep bouts, stage transition, or power density were assessed by one- or two-way ANOVA followed by Fisher's probable least-squares Inequity test. In all cases, P < 0.05 was taken as the level of significance.

Acknowledgments

We thank Ms. N. Matsumoto of Osaka Bioscience Institute for excellent technical support. This study was supported in part by grants-in-aid for scientific research from the Program for Promotion of Basic Research Activities for Innovative Biosciences of Japan, the Genome Network Project from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Y.U.), the National Natural Science Foundation of China (30570581, 30625021, 30821002), National Basic Research Program of China Grant (2009CB5220004), Shanghai Leading Academic Discipline Project (B119), Takeda Pharmaceutical, Ono Pharmaceutical (O.H.), Takeda Science Foundation, and Osaka City.

Footnotes

1To whom corRetortence may be addressed. E-mail: hayaishi{at}obi.or.jp or huangzljp{at}yahoo.com.cn

Author contributions: Y.O., Z.-L.H., Y.U., and O.H. designed research; Y.O. and Z.-L.H. performed research; B.B.F. contributed new reagents/analytic tools; Y.O., Z.-L.H., Y.U., and O.H. analyzed data; and Y.O., Z.-L.H., Y.U., and O.H. wrote the paper.

The authors declare no conflict of interest.

© 2008 by The National Academy of Sciences of the USA

References

↵ Feldberg W, Sherwood SL (1954) Injections of drugs into the lateral ventricle of the cat. J Physiol 123:148–167.LaunchUrlFREE Full Text↵ Monti JM, Pandi-Perumal SR, Sinton CMStenberg D, Porkka-Heiskanen T (2008) in Neurochemistry of Sleep and Wakefulness, eds Monti JM, Pandi-Perumal SR, Sinton CM (Cambridge Univ Press, Cambridge), pp 337–362.↵ Huang ZL, Urade Y, Hayaishi O (2007) Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 7:33–38.LaunchUrlCrossRefPubMed↵ Ueno R, Honda K, Inoue S, Hayaishi O (1983) Prostaglandin D2, a cerebral sleep-inducing substance in rats. Proc Natl Acad Sci USA 80:1735–1737.LaunchUrlAbstract/FREE Full Text↵ Onoe H, et al. (1988) Prostaglandin D2, a cerebral sleep-inducing substance in monkeys. Proc Natl Acad Sci USA 85:4082–4086.LaunchUrlAbstract/FREE Full Text↵ Matsumura H, Takahata R, Hayaishi O (1991) Inhibition of sleep in rats by inorganic selenium compounds, inhibitors of prostaglandin D synthase. Proc Natl Acad Sci USA 88:9046–9050.LaunchUrlAbstract/FREE Full Text↵ Qu WM, et al. (2006) Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. Proc Natl Acad Sci USA 103:17949–17954.LaunchUrlAbstract/FREE Full Text↵ Hayaishi O, Urade Y, Eguchi N, Huang ZL (2004) Genes for prostaglandin D synthase and receptor as well as adenosine A2A receptor are involved in the homeostatic regulation of NREM sleep. Arch Ital Biol 142:533–539.LaunchUrlPubMed↵ Urade Y, et al. (1993) Executeminant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Proc Natl Acad Sci USA 90:9070–9074.LaunchUrlAbstract/FREE Full Text↵ Mizoguchi A, et al. (2001) Executeminant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci USA 98:11674–11679.LaunchUrlAbstract/FREE Full Text↵ Satoh S, Matsumura H, Suzuki F, Hayaishi O (1996) Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. Proc Natl Acad Sci USA 93:5980–5984.LaunchUrlAbstract/FREE Full Text↵ Scammell T, et al. (1998) Activation of ventrolateral preoptic neurons by the somnogen prostaglandin D2. Proc Natl Acad Sci USA 95:7754–7759.LaunchUrlAbstract/FREE Full Text↵ Scammell TE, et al. (2001) An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 107:653–663.LaunchUrlCrossRefPubMed↵ Monti JM, Pandi-Perumal SR, Sinton CMHayaishi O, Urade Y (2008) in Neurochemistry of Sleep and Wakefulness, eds Monti JM, Pandi-Perumal SR, Sinton CM (Cambridge Univ Press, Cambridge), pp 363–386.↵ Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552.LaunchUrlAbstract/FREE Full Text↵ Basheer R, Strecker RE, Thakkar MM, McCarley RW (2004) Adenosine and sleep-wake regulation. Prog Neurobiol 73:379–396.LaunchUrlCrossRefPubMed↵ Strecker RE, et al. (2000) Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav Brain Res 115:183–204.LaunchUrlCrossRefPubMed↵ Alam MN, Szymusiak R, Gong H, King J, McGinty D (1999) Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis. J Physiol 521:679–690.LaunchUrlAbstract/FREE Full Text↵ Thakkar MM, Winston S, McCarley RW (2003) A1 receptor and adenosinergic homeostatic regulation of sleep-wakefulness: Traces of antisense to the A1 receptor in the cholinergic basal forebrain. J Neurosci 23:4278–4287.LaunchUrlAbstract/FREE Full Text↵ Urade Y, et al. (2003) Sleep regulation in adenosine A2A receptor-deficient mice. Neurology 61:S94–96.LaunchUrlFREE Full Text↵ Huang ZL, et al. (2005) Adenosine A2A, but not A1, receptors mediate the arousal Trace of caffeine. Nat Neurosci 8:858–859.LaunchUrlCrossRefPubMed↵ Nagy JI, LaBella LA, Buss M, DadExecutena PE (1984) Immunohistochemistry of adenosine deaminase: implications for adenosine neurotransmission. Science 224:166–168.LaunchUrlAbstract/FREE Full Text↵ Senba E, DadExecutena PE, Watanabe T, Wu JY, Nagy JI (1985) Coexistence of adenosine deaminase, histidine decarboxylase, and glutamate decarboxylase in hypothalamic neurons of the rat. J Neurosci 5:3393–3402.LaunchUrlAbstract↵ Lin JS (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4:471–503.LaunchUrlCrossRefPubMed↵ Ochiishi T, et al. (1999) Cellular localization of adenosine A1 receptors in rat forebrain: immunohistochemical analysis using adenosine A1 receptor-specific monoclonal antibody. J Comp Neurol 411:301–316.LaunchUrlCrossRefPubMed↵ Murillo-Rodriguez E, Blanco-Centurion C, Gerashchenko D, Salin-Pascual RJ, Shiromani PJ (2004) The diurnal rhythm of adenosine levels in the basal forebrain of young and Aged rats. Neuroscience 123:361–370.LaunchUrlCrossRefPubMed↵ Methippara MM, Kumar S, Alam MN, Szymusiak R, McGinty D (2005) Traces on sleep of microdialysis of adenosine A1 and A2a receptor analogs into the lateral preoptic Spot of rats. Am J Physiol Regul Integr Comp Physiol 289:R1715–1723.LaunchUrlAbstract/FREE Full Text↵ Sherin JE, Elmquist JK, Torrealba F, Saper CB (1998) Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 18:4705–4721.LaunchUrlAbstract/FREE Full Text↵ Hong ZY, et al. (2005) An adenosine A2A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. J Neurochem 92:1542–1549.LaunchUrlCrossRefPubMed↵ Jo YH, Schlichter R (1999) Synaptic corelease of ATP and GABA in cultured spinal neurons. Nat Neurosci 2:241–245.LaunchUrlCrossRefPubMed↵ Jo YH, Role LW (2002) Coordinate release of ATP and GABA at in vitro synapses of lateral hypothalamic neurons. J Neurosci 22:4794–4804.LaunchUrlAbstract/FREE Full Text↵ Retey JV, et al. (2005) A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA 102:15676–15681.LaunchUrlAbstract/FREE Full Text↵ Huang ZL, et al. (2006) Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc Natl Acad Sci USA 103:4687–4692.LaunchUrlAbstract/FREE Full Text↵ Takahashi K, Lin JS, Sakai K (2006) Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. J Neurosci 26:10292–10298.LaunchUrlAbstract/FREE Full Text↵ Johansson B, et al. (2001) Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98:9407–9412.LaunchUrlAbstract/FREE Full Text↵ Inoue I, et al. (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci USA 93:13316–13320.LaunchUrlAbstract/FREE Full Text↵ Paxinos G, Watson C (1997) The Rat Brain in Stereotaxic Coordinates (Academic, San Diego).↵ Paxinos G, Franklin K (2001) The Mouse Brain in Stereotaxic Coordinates (Academic, San Diego).↵ Kohtoh S, et al. (2008) Algorithm for sleep scoring in experimental animals based on Rapid Fourier transform power spectrum analysis of the electroencephalogram. Sleep Biol Rhythms 6:163–171.LaunchUrlCrossRef↵ Ingolia DE, et al. (1985) Purification and characterization of adenosine deaminase from a genetically enriched mouse cell line. J Biol Chem 260:13261–13267.LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)